Royal Bank of Canada
AUPH icon

Royal Bank of Canada’s Aurinia Pharmaceuticals AUPH Stock Holding History

Royal Bank of Canada’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$163K Sell
10,977
-4,116
-27% -$60.2K ﹤0.01% 4831
2025
Q4 		$240K Sell
15,093
-261,227
-95% -$3.7M ﹤0.01% 4653
2025
Q3 		$3.05M Sell
276,320
-4,198
-1% -$45.9K ﹤0.01% 3070
2025
Q2 		$2.38M Sell
280,518
-87,143
-24% -$699K ﹤0.01% 3155
2025
Q1 		$2.96M Buy
367,661
+145,179
+65% +$1.18M ﹤0.01% 2652
2024
Q4 		$2M Buy
222,482
+166,375
+297% +$1.36M ﹤0.01% 3032
2024
Q3 		$411K Buy
56,107
+13,817
+33% +$85.7K ﹤0.01% 4249
2024
Q2 		$241K Buy
42,290
+6,157
+17% +$32.4K ﹤0.01% 4606
2024
Q1 		$180K Sell
36,133
-18,332
-34% -$124K ﹤0.01% 4778
2023
Q4 		$490K Sell
54,465
-4,335
-7% -$35.7K ﹤0.01% 4282
2023
Q3 		$457K Buy
58,800
+33,198
+130% +$325K ﹤0.01% 4106
2023
Q2 		$248K Sell
25,602
-18,382
-42% -$191K ﹤0.01% 4546
2023
Q1 		$481K Buy
43,984
+12,369
+39% +$109K ﹤0.01% 3893
2022
Q4 		$136K Sell
31,615
-19,628
-38% -$114K ﹤0.01% 5219
2022
Q3 		$385K Buy
51,243
+1,197
+2% +$10.4K ﹤0.01% 4244
2022
Q2 		$503K Buy
50,046
+17,694
+55% +$198K ﹤0.01% 4091
2022
Q1 		$401K Sell
32,352
-5,533
-15% -$85.5K ﹤0.01% 4449
2021
Q4 		$867K Buy
37,885
+16,871
+80% +$400K ﹤0.01% 3962
2021
Q3 		$465K Sell
21,014
-114,804
-85% -$1.82M ﹤0.01% 4431
2021
Q2 		$1.76M Sell
135,818
-114,099
-46% -$1.45M ﹤0.01% 3177
2021
Q1 		$3.25M Buy
249,917
+108,742
+77% +$1.58M ﹤0.01% 2586
2020
Q4 		$1.95M Buy
141,175
+121,618
+622% +$1.77M ﹤0.01% 2939
2020
Q3 		$289K Buy
19,557
+13,917
+247% +$202K ﹤0.01% 4278
2020
Q2 		$92K Buy
5,640
+360
+7% +$5.76K ﹤0.01% 4897
2020
Q1 		$76K Buy
5,280
+1,870
+55% +$33K ﹤0.01% 4930
2019
Q4 		$70K Sell
3,410
-3,387
-50% -$31.2K ﹤0.01% 5270
2019
Q3 		$37K Buy
6,797
+3,549
+109% +$21.5K ﹤0.01% 5237
2019
Q2 		$21K Sell
3,248
-1,043
-24% -$6.65K ﹤0.01% 5678
2019
Q1 		$28K Sell
4,291
-5,431
-56% -$36K ﹤0.01% 5482
2018
Q4 		$66K Sell
9,722
-10,656
-52% -$61.4K ﹤0.01% 4953
2018
Q3 		$135K Buy
20,378
+3,424
+20% +$19.2K ﹤0.01% 4703
2018
Q2 		$95K Buy
16,954
+786
+5% +$4.38K ﹤0.01% 4826
2018
Q1 		$84K Sell
16,168
-939
-5% -$5.02K ﹤0.01% 4786
2017
Q4 		$77K Buy
17,107
+606
+4% +$3.36K ﹤0.01% 4956
2017
Q3 		$104K Sell
16,501
-467
-3% -$2.94K ﹤0.01% 4977
2017
Q2 		$104K Buy
16,968
+1,341
+9% +$9.04K ﹤0.01% 4740
2017
Q1 		$114K Buy
15,627
+4,779
+44% +$22.1K ﹤0.01% 4670
2016
Q4 		$23K Buy
10,848
+55
+0.5% +$177 ﹤0.01% 5692
2016
Q3 		$32K Buy
10,793
+25
+0.2% +$67 ﹤0.01% 5356
2016
Q2 		$30K Sell
10,768
-55
-0.5% -$150 ﹤0.01% 5327
2016
Q1 		$31K Sell
10,823
-20
-0.2% -$48 ﹤0.01% 5322
2015
Q4 		$27K Sell
10,843
-194
-2% -$527 ﹤0.01% 5584
2015
Q3 		$31K Buy
11,037
+118
+1% +$404 ﹤0.01% 5373
2015
Q2 		$33K Sell
10,919
-41
-0.4% -$152 ﹤0.01% 5438
2015
Q1 		$48K Sell
10,960
-405
-4% -$1.61K ﹤0.01% 4985
2014
Q4 		$41K Sell
11,365
-2,086
-16% -$7.43K ﹤0.01% 5135
2014
Q3 		$43K Buy
+13,451
New +$47.8K ﹤0.01% 5017

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Royal Bank of Canada's AUPH Position: Q1 2026 in Review

Royal Bank of Canada reduced its Aurinia Pharmaceuticals (AUPH) stake by 27% in Q1 2026, selling an estimated $60.2K and leaving 10,977 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #4831.

Royal Bank of Canada first reported a position in AUPH in Q3 2014 and has held it in 47 quarters since. The position peaked at $3.25M in Q1 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Royal Bank of Canada held 10,977 shares of Aurinia Pharmaceuticals worth $163K as of Q1 2026.
  • Royal Bank of Canada sold 4,116 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $60.2K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4831 holding.
  • Royal Bank of Canada first reported a position in Aurinia Pharmaceuticals in Q3 2014 and has held it in 47 quarters since.
  • Royal Bank of Canada's Aurinia Pharmaceuticals position peaked at $3.25M in Q1 2021.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.